source
- Biohaven targets muscle-sparing obesity market to compete with Lilly's GLP-1 drugsBiohaven is positioning itself to address obesity by developing treatments that preserve lean muscle, a differentiator from existing GLP-1 therapies. The company sees an opportunity to act as a "s…
- Sanofi proposes to cease negative statements about CSL's flu vaccine amid EU probeSanofi has offered to stop making disparaging comments about CSL's flu vaccine following an investigation launched by the European Commission. The offer comes two weeks after the Commission began p…